672 results about "Mycobacterium" patented technology

The invention provides recombinant escherichia coli with high yield of ergothioneine and a method for preparing ergothioneine, the recombinant escherichia coli co-expresses ergothioneine anabolic enzymes Egt1 and Egt2, the methyltransferase structural domain of the Egt1 is derived from trichoderma reesei, mycobacterium smegmatis EgtD or rhizopus nigricans, and the methyltransferase structural domain of the Egt2 is derived from the trichoderma reesei, the mycobacterium smegmatis EgtD or the rhizopus nigricans. The histidine sulfoxide synthase structural domain is derived from trichoderma reesei, schizosaccharomyces pombe or rhizopus nigricans, and the Egt2 is derived from claviceps purpurea, neurospora crassa or aspergillus niger. After the recombinant escherichia coli obtained by screening is cultured for 68 hours in a 5L fermentation tank, the yield of ergothioneine can reach 5g / L or above; wherein after recombinant escherichia coli co-expressing Egt1 enzyme (the structural domain of methyltransferase is derived from mycobacterium smegmatis EgtD, and the structural domain of histidine sulfoxide synthase is derived from trichoderma reesei) and Egt2 enzyme (derived from neurospora crassa) are cultured in a 5L fermentation tank for 68 hours, the yield of ergothioneine can reach 8.7 g / L, and the production intensity reaches 127.9 mg / (L.h).

The invention belongs to the technical field of probiotics and application thereof, and relates to a probiotic capable of reducing uric acid and a product thereof, in particular to a strain of Lentilactobacillusbuchneri strain ZD62 which is preserved in China Center for Type Culture Collection on March 14, 2024, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M2024469, and the preservation number is CCTCC NO: M2024469, the preservation number is CCTCC NO: M2024469, the preservation number is CCTCC NO: M2024469, and the preservation number is CCTCC NO: M2024469. The invention relates to a compound probiotic agent, which is prepared from Lentilactobacilli buchneri strain ZD62 and Mycobacterium fermentum ZD103, and is characterized in that the Mycobacterium fermentum ZD103 is prepared from Lentilactobacilli buchneri strain ZD62; the lactobacillus buchneri ZD62 and the mucus fermentum ZD103 provided by the invention have a good characteristic of reducing uric acid.

The invention provides an intracellular mycobacterium tuberculosis in-situ nucleic acid detection method based on CRISPR / Cas and application, and the method comprises the following steps: S1, designing crRNA and a primer pair of a mycobacterium tuberculosis target gene sequence, and synthesizing a single-stranded DNA fluorescent probe; s2, preparing a standard solution containing a target gene sequence, and incubating with a CRISPR / Cas12a system; s3, extracting nucleic acids of different types of bacteria, uniformly mixing the nucleic acids of different types of bacteria with the CRISPR / Cas12a system, and incubating; s4, incubating an attenuated strain of mycobacterium tuberculosis and the DNA fluorescent probe, infecting macrophages, and incubating to obtain infected cells; s5, electrically transferring a CRISPR / Cas12a system into the infected cells in S4 by utilizing an electroporation technology, incubating, and detecting the intensity of a fluorescence signal; and S6, performing quantitative and positioning analysis on the detected fluorescence signal to complete detection, and directly introducing a CRISPR / Cas12a system into the macrophage by adopting an electroporation technology to realize intracellular in-situ detection, thereby avoiding the operation complexity of a nucleic acid extraction link and the loss of detection sensitivity in the prior art.

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The invention discloses an application of cryptotanshinone in preparation of an anti-mycobacterium tuberculosis drug, and relates to the technical field of bioengineering. The molecular formula of the valerianin disclosed by the invention is C19H20O3. The mycobacterium tuberculosis is a mycobacterium tuberculosis H37Rv strain. Cryptotanshinone is disclosed as a natural-source compound for the first time, has the dual advantages of high efficiency and low toxicity, has an obvious effect of resisting mycobacterium tuberculosis, provides a brand new candidate drug scheme with development potential for solving the difficulty of tuberculosis treatment, and has great scientific value and application prospect.

The invention discloses two mycobacterium bacteriophages and application thereof. The two bacteriophages both have a splitting spectrum width and efficient splitting capability, can specifically realize effective splitting of mycobacteria of five specific sequence types, and are further applied to the field of prevention and control of mycobacteria. Specifically, the bacteriophage MP2435 and the bacteriophage MP2451 not only can effectively inhibit the proliferation process of mycobacteria and block the formation of a biofilm of the mycobacteria, but also can efficiently kill the mycobacteria in a milk matrix; meanwhile, the two bacteriophages can still keep relatively high activity under the conditions that the temperature is 37-65 DEG C and the pH value is 3-12, and the bactericidal activity of the bacteriophages can be stably maintained even in acid-base, high-temperature and ultraviolet-containing extreme environments. Through the characteristics, the application scene and application range of the bacteriophage in mycobacterium prevention and control are remarkably widened, and an efficient and stable novel technical means is provided for biological prevention and control of mycobacterium.

The invention discloses a method for rapidly detecting mycobacteria. The method comprises the following steps: using a primer pair for detecting the Mycobacterium tuberculosis, wherein the primer pair comprises an upstream primer and a downstream primer; the upstream primer comprises a nucleotide sequence as shown in SEQ ID NO: 1 or 2, and the downstream primer comprises a nucleotide sequence as shown in any one of SEQ ID NO: 3-6. According to the present invention, the RNA of the MTB viable bacteria in the biological sample can be rapidly and accurately detected with high sensitivity, the detection limit is reduced by 1000 times compared with the existing NASBA kit, the template requirement is reduced, and the better choice is provided for the instant detection of MTB.

The invention provides a primer group and a kit for detecting bovine mycobacterium paratuberculosis based on a recombinase isothermal amplification technology and application, and relates to the technical field of biological detection.The primer group comprises a forward primer MAP-F3, a reverse primer MAP-R3 and a specific fluorescent probe MAP-P3 and has good specificity; the sensitivity reaches 10fg / mu L, which is more sensitive than that of a colloidal gold test strip, the dependence on equipment is broken through, and the detection result is more accurate. The technical problem that in the prior art, it is difficult to distinguish bovine mycobacterium paratuberculosis from other pathogens through a detection method, or the detection process is tedious is solved. According to the prepared reagent or kit, the liquid preparation process is simple, the whole amplification process can be completed only in 30 min, the amplification yield can reach 109-1010 copies, the method is rapid and efficient, the amplification result can be directly judged according to fluorescence data, other auxiliary means are not needed, and the method is suitable for field detection.

The invention discloses a traditional Chinese medicine composition for resisting giant frog blue eye disease pathogen Elizabeth mileli and application of the traditional Chinese medicine composition, and relates to the technical field of aquaculture disease prevention and treatment. It is found for the first time that the radix scutellariae has a good effect of inhibiting the Elizabeth mille, and the herba houttuyniae does not have the effect of inhibiting the Elizabeth mille but can enhance the inhibiting effect of the radix scutellariae on the Elizabeth mille, that is, the herba houttuyniae has a synergistic enhancement effect; the traditional Chinese medicine composition of the radix scutellariae and the herba houttuyniae is expected to be applied to treatment of the blue eye disease of the giant spiny frog, and the Chinese herbal medicine composition is used for replacing antibiotics in the breeding process.

The present invention relates to a recombinant Mycobacterium bovis BCG strain comprising a plasmid having a short guide RNA (sgRNA) target sequence for knocking out the Mb3739 gene. Also provided are vaccine compositions for eliciting an immune response against Mycobacterium tuberculosis comprising a recombinant Mycobacterium bovis BCG strain engineered to activate the NOD-1 pathway. The recombinant Mycobacterium bovis BCG strain or vaccine composition can be used in a method against an immune response initiated by Mycobacterium tuberculosis. The invention also relates to a method for obtaining the recombinant bovine mycobacterium BCG strain.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention relates to the technical field of gene detection, and discloses a mycobacterium tuberculosis drug resistance gene detection data analysis system which comprises a data import module, a signal correction module, a feature extraction module, a multi-stage interpretation module, a result fusion module and a report generation module. The system performs baseline drift correction, abnormal point detection and nonlinear normalization on a fluorescence intensity value output by a detector, extracts multi-dimensional features such as peak intensity, a mutation ratio, a consistency coefficient and an in-batch difference index, and constructs a dynamic threshold function to realize wild type and mutation type layered judgment. A drug resistance risk conclusion is generated through drug resistance characteristic matrix mapping, a standardized detection report is output, and intelligent analysis of a detection result and automatic report generation are achieved. Through multi-stage signal correction, multi-dimensional feature extraction and dynamic threshold interpretation, intelligent analysis and standardized report output of a mycobacterium tuberculosis drug resistance gene detection result are realized, and data judgment accuracy and clinical application efficiency are improved.

The present invention provides a microfluidic detection chip for tuberculosis-specific cellular immunity, belonging to the technical field of Mycobacterium tuberculosis detection. The chip is primarily composed of a three-layer structure, assembled sequentially from bottom to top: a chip bottom sealing plate, a chip substrate, and a chip top sealing plate. The chip is equipped with detection units for multiple samples, capable of simultaneously performing IGRA detection of negative controls, positive controls, and a sample control of 1-8 test samples. Furthermore, the present invention provides an assembly process for a centrifugal microfluidic detection chip for tuberculosis-specific cellular immunity, as well as a detection method and application of chip-based IGRA using the chip. The chip-based IGRA demonstrated a 100% overall concordance rate between test results and those of conventional IGRA. Furthermore, the chip-based IGRA enables detection of very small numbers of test samples, while improving the throughput and speed of IGRA detection, thus showing significant application prospects for IGRA detection of large numbers of clinical samples.

The invention discloses a combination of blocking agents for detecting drug resistance of mycobacterium tuberculosis. The combination comprises a first peptide nucleic acid blocking agent, a second peptide nucleic acid blocking agent, a third peptide nucleic acid blocking agent and a fourth peptide nucleic acid blocking agent. The first peptide nucleic acid blocker covers codons 511 and 513 of the rpoB gene. The second peptide nucleic acid blocker covers the codon 516 of the rpoB gene. And the third peptide nucleic acid blocking agent covers the codon 526 of the rpoB gene. And the fourth peptide nucleic acid blocking agent covers codons 531 and 533 of the rpoB gene. The respective sequences of the first peptide nucleic acid blocker, the second peptide nucleic acid blocker, the third peptide nucleic acid blocker, and the fourth peptide nucleic acid blocker match the wild type of the corresponding sequence of the rpoB gene. The invention also provides a kit and a method for detecting the drug resistance of mycobacterium tuberculosis.

The invention provides sgRNA for detecting tuberculosis based on an RPA-CRISPR Cas12b technology, a kit, a detection method and application, and belongs to the technical field of molecular detection. The invention provides sgRNA (single guide ribonucleic acid) for detecting mycobacteria. The sgRNA comprises sgRNA-6110 of which the nucleotide sequence is shown as SEQ ID NO: 1 and / or sgRNA-1081 of which the nucleotide sequence is shown as SEQ ID NO: 2. The sgRNA provided by the invention can specifically recognize and combine high-conservative-degree target sequences IS6110 and IS1081 of mycobacterium tuberculosis and / or mycobacterium bovis, and can be used for instant test of human and livestock tuberculosis pathogenic bacteria mycobacterium tuberculosis and / or mycobacterium bovis.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen, which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, at least one mycobacterium tuberculosis PE / PPE family antigen Rv1759c (PE-PGRS family protein WAG22) or immunocompetence fragments thereof, and at least one immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

The invention discloses an electrochemical biosensor for detecting mycobacterium tuberculosis. The sensor takes a porous membrane as a base material, the inner wall of a pore channel of the porous membrane is co-modified with a polydopamine (PDA) and conductive carbon material composite layer, and an amino-modified specific capture probe based on a mycobacterium tuberculosis ESAT-6 gene is fixed on a modification layer through covalent binding. When a target gene is captured by a probe, the volume effect of the target gene causes blockage of a porous channel of the porous membrane, so that electrochemical signals (such as current) of the sensor are changed, and high-sensitivity and specific detection of mycobacterium tuberculosis is realized. According to the invention, a porous structure, biological probe specific fixation and an electrochemical signal conversion technology are combined, and a novel efficient tool is provided for rapid diagnosis of tuberculosis.

The invention relates to the technical field of biological medicines, in particular to a tuberculosis vaccine antigen and a vaccine. In particular to application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, in the application, the sequence of the Rv1787 gene or an encoding product thereof is defined, and the Rv1787 gene and the encoding product thereof serve as antigens, have mycobacterium tuberculosis specificity, and can be used for preparing a vaccine for preventing and / or treating tuberculosis. According to the mycobacterium tuberculosis vaccine, identification and response of an organism immune system to mycobacterium tuberculosis can be accurately stimulated, non-specific immune response to other normal tissues is avoided, a brand new and specific molecular target spot is provided for preventing and treating tuberculosis, and the limitation that a traditional vaccine depends on a single antigen or an attenuated strain is broken through. A specific expression product of the gene can stimulate directional recognition and attack of an organism immune system on mycobacterium tuberculosis, the pertinence and effectiveness of vaccines are remarkably improved, and a new path is provided for solving the problem of tuberculosis prevention and treatment.

The present invention relates to specific binding molecules which bind to the HLA-E restricted peptide RLPAKAPLL (SEQ ID NO: 1) derived from Mycobacterium tuberculosis enoyl-ACP reductase. Said specific binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious disease.

The invention discloses a method for establishing indirect ELISA (enzyme-linked immunosorbent assay) for detecting mycobacterium bovis Lprl, which comprises the following steps: preparing mycobacterium bovis Lprl protein, taking the purified protein as an antigen, and determining conditions such as optimal antigen coating concentration, serum dilution, serum incubation time, secondary antibody dilution concentration, incubation time and the like. The established indirect ELISA detection method does not have cross reaction with other bovine pathogens, the specificity is good, the detection accuracy is high, and the total coincidence rate of test results of intradermal allergy with bovine tubercle bacillus is 95.8%; the intra-batch variation coefficient of the detected samples is 2.43%-3.61%, the inter-batch variation coefficient is 2.83%-3.96%, and the intra-batch variation coefficient and the inter-batch variation coefficient are both smaller than 10%. A new diagnosis target is developed, the established indirect ELISA method has the characteristics of high sensitivity, strong specificity, good repeatability and the like, the operation is easy, and a new method is provided for the detection work of the mycobacterium bovis.

The present invention relates to the field of biomedicine, and in particular to the use of Mycobacterium finschii in the preparation of a drug for treating acute graft-versus-host disease. The present invention clarifies a specific strain of Mycobacterium finschii that has the effect of inhibiting acute graft-versus-host disease. By obtaining a single strain of bacteria with an inhibitory effect, it is helpful to prepare drugs in a standardized and streamlined manner, thereby obtaining drugs with clear ingredients, strict quality testing, and direct clinical application, so that the same standard drug can be widely used in patients with acute graft-versus-host disease, thereby improving the universality of the drug.

The present invention provides a bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, the bacteriophage having a genome containing a nucleic acid sequence represented by the genome of the bacteriophage specified by the preservation number NITE BP-03513 or NITE BP-03514 or the preservation number NITE BP-03918, the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, and the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis. The capsid of the phage is connected with the cell-penetrating peptide through a tag.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present invention provides an electrochemical aptamer sensor for detecting Mycobacterium tuberculosis ESAT‑6 antigen. The sandwich electrochemical biosensor uses a new type of MXene@Hemin‑AuNPs nanozyme as a signal amplifier and N‑CNTs‑AuNPs as a sensing interface to detect the Mycobacterium tuberculosis-specific antigen ESAT‑6 in the serum of tuberculosis patients, providing a new method for the diagnosis of tuberculosis.

The invention relates to a photoactivated carbonyl manganese (I) complex and a preparation method and application thereof in antibiosis. The manganese (I) complex has a good photoactivation antibacterial effect. Specifically, the manganese carbonyl (I) complex can be photoactivated to release carbon monoxide and ligands under the irradiation of white light. By detecting MIC90 of the photoactivated carbonyl manganese (I) complex to different bacteria, the result shows that the photoactivated carbonyl manganese (I) complex has a better antibacterial effect on mycobacterium smegmatis.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

Provided here are nucleic acid constructs containing a Mycobacterium tuberculosis genome comprising a mutation (such as a deletion) of the sigH gene (AsigH) and a mutation (such as a deletion) of at least one additional gene, and mutant Mycobacterium tuberculosis encoded by the nucleic acid constructs. Also provided are methods of making such nucleic acid constructs and Mycobacterium tuberculosis mutants, and uses thereof. The construct can stimulate an immune response against Mycobacterium tuberculosis in a subject, and can be used as live attenuated vaccines.

Use of Mycobacterium vaccae, for example strain ATCC 15483, for the treatment or prevention of weight gain, visceral adipose tissue (VAT), obesity, obesity-related metabolic diseases and stress-related disorders.

The invention discloses an application of a single base / amino acid mutation of a bovine DDX58 gene in anti-tuberculosis, belongs to the technical field of bovine tuberculosis prevention and treatment, an application of a single base mutation of a bovine DDX58 gene in anti-tuberculosis, the CDS sequence of the bovine DDX58 gene is shown in SEQ ID NO.1, the amino acid sequence is shown in SEQ ID NO.2, and the single base mutation is located at the 11603839th nucleotide from the 5′ end of chromosome 8 of the ARS-UCD1.2 version reference sequence of the bovine genome. The single base mutation of the bovine DDX58 gene provided by the present invention has a significant effect on the production amount of type I interferon and the clearance effect of macrophages on Mycobacterium tuberculosis, and is highly linked to the anti-tuberculosis trait of the bovine; the single base / amino acid mutation of the bovine DDX58 gene provided can be used as a bovine tuberculosis resistance linkage site, used for genotype selection in bovine tuberculosis resistance breeding, thereby simplifying the selection method and shortening the selection time.

The invention belongs to the field of pharmacology, and discloses a crystal form I of an oxazolidinone antibacterial candidate new drug OTB-658, a preparation method of the crystal form I, a composition of the crystal form I and application of the crystal form I. Specifically, the invention relates to a crystal form I of N-(((3S, 3aS)-8-fluoro-1-oxo-7-thiomorpholinyl-3a, 4-dihydro-1H, 3H-benzo [b] oxazole [3, 4-d] [1, 4] oxazine-3-yl) methyl) acetamide, namely OTB-658, and a preparation method thereof. The OTB-658 crystal form I is used as an active pharmaceutical ingredient to prepare drugs for treating and / or preventing bacteria, especially mycobacterium tuberculosis infectious diseases. # imgabs0 #